In contrast, NSCLC tumors with wild-type EGFR receptors often do not respond to EGFR inhibitor therapy and actually are more responsive to traditional chemotherapy.[8] As a result, identifying EGFR mutation status before initiation of EGFR-TKI therapy is advocated for patients with NSCLC.[11]. Here, EGFR is linked to non-small cell lung carcinoma.